| Pharmacokinetics of butyric acid derivative with xylitol. | |
| | |
MedLine Citation:
|
PMID: 1820907 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The short chain fatty acids, especially butyric acid salts have interesting biological properties. In some cases, transformed cells can recover a normal phenotype and in animal, butyrate salts increase antitumor resistance. Butyrate may be considered as possibly useful for antitumor therapy. But these products exhibit two essential disadvantages which restrict their clinical use in man: high concentrations required to achieve therapeutic effects and rapid excretion with short half life. In order to optimize the clinical use of butyrate, we studied a n-butyric acid ester obtained with xylitol selected for its physiological and metabolic inertia. Structure determination of tributyryl xylitol was carried out by mass and NMR spectrometry (MW = 344). The low toxicity and the antitumor effects of this ester, especially in association with Corynebacterium parvum and interferon, confirm its therapeutic interest. The slow excretion of this prodrug should make butyrate clinical use easier by preventing extensive systemic metabolism and metabolic side-effects due to cations of butyrate salts. |
| | |
Authors:
|
G Desmet; M Brazier; J Cerutti; C Chany; M L Arnould-Guerin |
Related Documents
:
|
4577487 - Production of a sporulation pigment by streptomyces venezuelae. 3079997 - Further studies on the inhibition of pepsin by bile salts. 1808607 - Solubilization and wetting effects of bile salts on the dissolution of steroids. 2153027 - An investigation of the dissociation and denaturation of legumin by salts using laser l... 16326817 - In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs... 14984087 - Marmenol: a 7-geranyloxycoumarin from the leaves of aegle marmelos corr. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of drug metabolism and pharmacokinetics Volume: Spec No 3 ISSN: 0378-7966 ISO Abbreviation: Eur J Drug Metab Pharmacokinet Publication Date: 1991 |
Date Detail:
|
Created Date: 1992-08-10 Completed Date: 1992-08-10 Revised Date: 2011-02-02 |
Medline Journal Info:
|
Nlm Unique ID: 7608491 Medline TA: Eur J Drug Metab Pharmacokinet Country: FRANCE |
Other Details:
|
Languages: eng Pagination: 348-51 Citation Subset: IM |
Affiliation:
|
Laboratoire d'Hormonologie, C.H.U., Amiens, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / pharmacology Butyrates / chemical synthesis, pharmacokinetics*, pharmacology Lethal Dose 50 Magnetic Resonance Spectroscopy Mass Spectrometry Mice Prodrugs / chemical synthesis, pharmacokinetics* Rabbits Sarcoma, Experimental / drug therapy Xylitol / analogs & derivatives, pharmacokinetics*, pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Butyrates; 0/Prodrugs; 87-99-0/Xylitol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacoki...
Next Document: Homeostatic equilibrium of L-carnitine family before and after i.v. administration of propionyl-L-ca...